Vortioxetine (Trintellix) Prescribing Guidelines
Initiation and Dosing
Start vortioxetine at 10 mg orally once daily without regard to meals, then increase to 20 mg daily as tolerated 1. This represents the FDA-approved dosing strategy that balances efficacy with tolerability.
Dosing Algorithm:
- Standard initiation: 10 mg daily
- Target dose: 20 mg daily (most effective dose in U.S. studies) 2
- For intolerance: Reduce to 5 mg daily if higher doses not tolerated 1
- CYP2D6 poor metabolizers: Maximum 10 mg daily 1
Titration Schedule:
The FDA label does not specify a mandatory titration timeline from 10 mg to 20 mg 1. Clinical judgment should guide the increase based on tolerability, though research suggests steady-state concentrations are achieved within approximately 2 weeks at any given dose 2, 3. For patients requiring slower titration, oral drops (20 mg/mL) allow 1 mg/day incremental increases, reaching steady-state in 14-18 days 4.
Contraindications
Absolute contraindications 1:
- Hypersensitivity to vortioxetine or formulation components
- MAOIs: Do not use within 21 days of stopping vortioxetine; do not start vortioxetine within 14 days of stopping an MAOI
- Concurrent linezolid or IV methylene blue
Critical caveat for obese patients: Washout half-life is significantly prolonged in obesity (3.26 days vs 2.21 days in normal weight), requiring extended MAOI washout periods beyond the standard 21 days to avoid serotonin syndrome 5.
Monitoring Guidelines
Begin monitoring within 1-2 weeks of initiation and continue regularly 6. This early assessment window is critical for detecting both therapeutic response and adverse effects.
Specific Monitoring Parameters:
Weeks 1-2 6:
- Suicidal ideation/behavior (especially in patients ≤24 years, though risk extends to age 64) 7
- Nausea (most common adverse effect, dose-dependent) 2, 8
- Activation symptoms (anxiety, agitation, insomnia)
Weeks 6-8 6:
- Modify treatment if inadequate response by 6-8 weeks - this is a firm decision point
- Assess for response (≥50% symptom reduction)
Ongoing monitoring:
- Bleeding risk: Particularly with concurrent NSAIDs, antiplatelet agents, or anticoagulants 1
- Hyponatremia/SIADH: Especially in elderly or volume-depleted patients 1
- Sexual dysfunction: Systematically assess as vortioxetine may cause sexual side effects 1
- Angle-closure glaucoma: Screen patients with untreated narrow angles 1
- Mania/hypomania activation: Screen for bipolar disorder before initiating 1
Cardiovascular Monitoring:
Vortioxetine demonstrates favorable cardiovascular safety with no QTc prolongation, minimal blood pressure/heart rate effects, and no significant platelet aggregation effects 9. However, post-marketing surveillance identified QT prolongation signals (ROR = 3.14) 8, warranting baseline ECG consideration in high-risk patients.
Adverse Event Timeline:
Most adverse events occur within the first month (median onset: 15 days) 8. Nausea, anxiety, vomiting, headache, and somnolence are most common 8.
Discontinuation
Vortioxetine can be discontinued abruptly 1. However, for doses of 15-20 mg daily, taper to 10 mg daily for one week before full discontinuation to minimize potential withdrawal symptoms 1.
Duration of Treatment
Continue treatment for 4-9 months after satisfactory response for first episode MDD 6. For patients with ≥2 prior episodes, longer maintenance therapy is beneficial 6.
Drug Interactions Requiring Dose Adjustment
- Strong CYP2D6 inhibitors (e.g., bupropion): Reduce vortioxetine dose by half 1
- Strong CYP inducers (e.g., rifampin): Consider increasing vortioxetine up to 3 times the original dose if co-administered >14 days (do not exceed maximum recommended dose) 1